The estimated Net Worth of Aaron G.L. Fletcher is at least $383 Thousand dollars as of 22 November 2022. Aaron Fletcher owns over 43,470 units of Cue Biopharma Inc stock worth over $84,647 and over the last 5 years he sold CUE stock worth over $0. In addition, he makes $298,525 as Independent Director at Cue Biopharma Inc.
Sign up
Aaron Fletcher CUE stock SEC Form 4 insiders trading
Aaron has made over 12 trades of the Cue Biopharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 43,470 units of CUE stock worth $49,991 on 22 November 2022.
The largest trade he's ever made was buying 735,000 units of Cue Biopharma Inc stock on 31 March 2022 worth over $3,498,600. On average, Aaron trades about 53,287 units every 35 days since 2019. As of 22 November 2022 he still owns at least 143,470 units of Cue Biopharma Inc stock.
You can see the complete history of Aaron Fletcher stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Aaron Fletcher biography
Dr. Aaron G.L. Fletcher Ph.D. serves as Independent Director of the Company. Dr. Fletcher has served as founder and President of Bios Research, a financial services firm that provides public equity research in the healthcare industry tailored to institutional firms and large family offices, since 2012. Since 2014, Dr. Fletcher has also served as Managing Partner of Bios Partners, LP, a venture capital firm focused on investment in early-stage and growth-stage biotech and medical device companies. Dr. Fletcher also serves as director of TFF Pharmaceuticals, Inc. (Nasdaq: TFFP), Acute Therapeutics, AbiliTech Medical, Inc. and Cognition Therapeutics, Inc. Dr. Fletcher holds a Ph.D. in Biochemistry from Colorado State University and serves as a visiting professor at Dallas Baptist University. The Board believes Dr. Fletcher’s public company experience, financial expertise, and experience overseeing investments in the healthcare industry provides him with the qualifications and skills to serve on our board of directors.
What is the salary of Aaron Fletcher?
As the Independent Director of Cue Biopharma Inc, the total compensation of Aaron Fletcher at Cue Biopharma Inc is $298,525. There are 6 executives at Cue Biopharma Inc getting paid more, with Anish Suri having the highest compensation of $4,559,810.
How old is Aaron Fletcher?
Aaron Fletcher is 40, he's been the Independent Director of Cue Biopharma Inc since 2019. There are 19 older and no younger executives at Cue Biopharma Inc. The oldest executive at Cue Biopharma Inc is Frederick Driscoll, 70, who is the Independent Director.
What's Aaron Fletcher's mailing address?
Aaron's mailing address filed with the SEC is C/O CUE BIOPHARMA INC., 40 GUEST STREET, BOSTON, MA, 02135.
Insiders trading at Cue Biopharma Inc
Over the last 7 years, insiders at Cue Biopharma Inc have traded over $1,426,672 worth of Cue Biopharma Inc stock and bought 1,194,685 units worth $5,848,356 . The most active insiders traders include Daniel R Passeri, Aaron G.L. Fletcher, and Barry J. Simon. On average, Cue Biopharma Inc executives and independent directors trade stock every 37 days with the average trade being worth of $18,162. The most recent stock trade was executed by Anish Suri on 25 August 2023, trading 4,000 units of CUE stock currently worth $11,040.
What does Cue Biopharma Inc do?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
What does Cue Biopharma Inc's logo look like?
Complete history of Aaron Fletcher stock trades at Cue Biopharma Inc, Swk Corp, and Tff Pharmaceuticals Inc
Cue Biopharma Inc executives and stock owners
Cue Biopharma Inc executives and other stock owners filed with the SEC include:
-
Anish Suri,
President, Chief Scientific Officer -
Daniel Passeri,
Chief Executive Officer, Director -
Daniel R. Passeri M.Sc., MSc., J.D.,
CEO & Director -
Colin Sandercock,
Senior Vice President, General Counsel, Secretary -
Dr. Anish Suri Ph.D.,
Pres & Chief Scientific Officer -
Kerri-Ann Millar,
Chief Financial Officer -
Aaron Fletcher,
Independent Director -
Barry Simon,
Independent Director -
Peter Kiener,
Independent Director -
Frederick Driscoll,
Independent Director -
Frank Morich,
Independent Chairman of the Board -
Cameron Gray,
Independent Director -
Tamar Howson,
Director -
Kenneth Pienta,
Chief Medical Officer -
Kerri-Ann Millar,
Chief Financial Officer -
Dr. Kenneth J. Pienta,
Acting Chief Medical Officer -
Dr. Ronald D. Seidel III, Ph.D.,
Co-Founder -
Dr. Matteo Levisetti M.D.,
Sr. VP of Clinical Devel. -
Dr. Ronald D. Seidel III,
Exec. VP and Head of R&D -
Colin G. Sandercock J.D., MSE,
Sr. VP, Gen. Counsel & Sec. -
George B. Zavoico Ph.D.,
VP of Investor Relations & Corp. Devel. -
Dr. Steven C. Almo,
Co-Founder and Chairman of Scientific & Clinical Advisory Board -
Dr. Rodolfo J. Chaparro,
Co-Founder & Sr. Advisor -
Bethany Mancilla,
SVP and Chief Business Officer -
Ronald D. Iii Seidel,
EVP, Head of R&D -
Christopher A Marlett,
Director -
Anthony Digiandomenico,
Director -
Rodolfo Chaparro,
EVP, Head of Immunology -
Steven L Mcknight,
Director -
Patricia Nasshorn,
Chief Business Officer -
Matteo Levisetti,
Chief Medical Officer -
Michael J Fox,
-
Pamela Garzone,
-
Patrick Verheyen,
-
Lucinda Warren,
CHIEF BUSINESS OFFICER